Phase I multiple-dose trial of inhaled ALN RSV01 in volunteers.
Latest Information Update: 18 Dec 2007
Price :
$35 *
At a glance
- Drugs Asvasiran sodium (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacokinetics
- 14 Dec 2007 Results have been presented at the 18th Annual Drug Delivery to the Lungs meeting in December 2007.
- 14 Dec 2007 Status changed from in progress to completed.
- 15 Nov 2007 Enrolment has been completed and safety results are expected at the end of 2007.